The present findings provide novel insight into the clinical significance of the ADRB3 rs4994 polymorphism concerning NAFLD development and may therefore accelerate the introduction of further preventive measures against NAFLD based on a patient's genetic background. The gene discussed is ADRB3; the disease is metabolic dysfunction-associated steatotic liver disease.